VIVS — VivoSim Labs, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1497253 ·
Last close
$0.22
Market Cap
$2.95M
52W High
$3.54
52W Low
$0.22
ADV30
956,823
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 18,000 | — | -2,759,000 | -1,338,000 | 3,847,000 | 1,670,000 | 6,193,000 |
| Mar 2026 | 40,000 | 40,000 | -3,187,000 | -5,764,000 | 7,386,000 | 5,024,000 | 8,485,000 |
| Dec 2025 | 26,000 | 26,000 | -2,750,000 | -2,691,000 | 6,960,000 | 4,288,000 | 2,519,000 |
| Sep 2025 | 28,000 | 28,000 | -2,635,000 | -2,545,000 | 9,686,000 | 6,677,000 | 2,621,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,827,000
Investing CF
$94,000
Financing CF
$4,445,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.43
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,000,000
Inventory
$0
Receivables
$1,046,000
ST Investments
—
EBIT TTM
$-13,829,000
Pretax Income TTM
$-13,841,000
Interest Exp TTM
$12,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$112,000
EBITDA
$-11,137,000
Free Cash Flow
$-7,575,375
Enterprise Value
$2,850,208
Total Cash
$1,670,000
Total Debt
$316,000
Shares Out
13,390,789
Trailing EPS
$-4.46
Book Value
$1.70
ROE
-343.1%
ROA
-89.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 131,000 | -11,487,000 | -13,843,000 | 7,386,000 | 8,485,000 | -1,099,000 | -10,827,000 |
| Mar 2025 | 144,000 | -12,616,000 | -2,488,000 | 14,650,000 | 4,158,000 | 10,492,000 | -9,461,000 |
| Mar 2024 | 109,000 | -15,086,000 | -14,671,000 | 6,349,000 | 2,748,000 | 3,601,000 | -14,653,000 |
| Mar 2023 | 370,000 | -17,731,000 | -17,259,000 | 20,313,000 | 4,984,000 | 15,329,000 | -12,408,000 |
| Mar 2022 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | $2.92M | $1.13 | — |
| BCAB | BioAtla, Inc. | $2.47M | $1.48 | — |
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
| PMCB | PharmaCyte Biotech, Inc. | $4.73M | $0.44 | — |
News headlines (Yahoo Finance, 1h cache)
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
2026-07-21 14:28 · Yahoo
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
2026-07-21 12:05 · Yahoo
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
2026-07-16 12:30 · Yahoo
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
2026-07-15 14:46 · Yahoo
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
2026-07-15 12:05 · Yahoo
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
2026-06-29 12:05 · Yahoo
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
2026-04-28 12:05 · Yahoo
VivoSim Announces Pricing of up to a $4 Million Public Offering
2026-04-01 12:05 · Yahoo
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
2026-09-16 12:05 · Yahoo
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
2026-09-01 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.